Related references
Note: Only part of the references are listed.Fulminant myocarditis with myositis after treatment with immune checkpoint inhibitors
Jose Ramon Gonzalez-Juanatey et al.
MEDICINA CLINICA (2022)
An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer
Ken Naganuma et al.
INTERNAL MEDICINE (2022)
Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
Yue-Bei Luo et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
Wendy Bernhard et al.
BMC CANCER (2021)
Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
Whitney Barham et al.
FRONTIERS IN IMMUNOLOGY (2021)
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Walid Shalata et al.
CANCERS (2021)
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco et al.
LANCET ONCOLOGY (2021)
A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer
Masaru Komatsu et al.
BMC GASTROENTEROLOGY (2021)
Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report
Antonio Portoles Hernandez et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)
A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil
Mette Syberg Jespersen et al.
EUROPEAN HEART JOURNAL-CASE REPORTS (2021)
Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review
Alexander Vartanov et al.
RESPIRATORY MEDICINE CASE REPORTS (2021)
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
Magid Awadalla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
J. Doms et al.
ANNALS OF ONCOLOGY (2020)
Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report
Tanner Hardy et al.
CARDIOVASCULAR PATHOLOGY (2020)
Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
Qian Xing et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report
Charles Szuchan et al.
EUROPEAN HEART JOURNAL-CASE REPORTS (2020)
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J-P Machiels et al.
ANNALS OF ONCOLOGY (2020)
A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China
Feng Wang et al.
CHINESE CLINICAL ONCOLOGY (2020)
Cardiovascular toxicities associated with immune checkpoint inhibitors
Jiun-Ruey Hu et al.
CARDIOVASCULAR RESEARCH (2019)
Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab
S. D. Saibil et al.
CURRENT ONCOLOGY (2019)
Cardiovascular Toxicities of Immune Checkpoint Inhibitors JACC Review Topic of the Week
Somedeb Ball et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Cardiac Complications in Immune Checkpoint Inhibition Therapy
Kazuko Tajiri et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2019)
Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Julie Charles et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists
Mauro Frigeri et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab
Fadi Nasr et al.
EUROPEAN JOURNAL OF CANCER (2018)
Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity
Nicolas Martinez-Calle et al.
HAEMATOLOGICA (2018)
Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring
Yumi Katsume et al.
INTERNAL MEDICINE (2018)
Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin
Varun Jain et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Tomas G. Neilan et al.
ONCOLOGIST (2018)
Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity
Nicolas Martinez-Calle et al.
HAEMATOLOGICA (2018)
Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia
David D. Berg et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
Juliane Behling et al.
MELANOMA RESEARCH (2017)
Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
Yoko Fukasawa et al.
CASE REPORTS IN ONCOLOGY (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Rebecca Y. Tay et al.
BRITISH JOURNAL OF CANCER (2017)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Share Paper
